Seeking Alpha
View as an RSS Feed

Probio Invest  

PRO Articles
PRO articles cover stocks that fly under most investors' radar screens.
  • Osiris Therapeutics' Survival In Doubt After Losing 'Pass-Through' Status In 2015
       • Jul. 11, 2014 OSIR 14 Comments

    Summary

    • CMS proposes the pass-through status of Grafix will expire on Dec 31, 2014.
    • The decision will significantly decrease the revenue of Osiris.
    • Osiris' survival is in doubt under the reduced pricing schedule.